Pioglitazone prevents corporal veno‐occlusive dysfunction in a rat model of type 2 diabetes mellitus
OBJECTIVES To determine whether corporal veno‐occlusive dysfunction (CVOD), corporal smooth muscle (SM) loss, fibrosis and oxidative stress occur in a rat model of type 2 diabetes, and whether these are counteracted by pioglitazone, as pioglitazone is vasculoprotective, and corporal SM is an extensi...
Gespeichert in:
| Veröffentlicht in: | BJU international 2006-07, Vol.98 (1), p.116-124 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 124 |
|---|---|
| container_issue | 1 |
| container_start_page | 116 |
| container_title | BJU international |
| container_volume | 98 |
| creator | KOVANECZ, ISTVAN FERRINI, MONICA G. VERNET, DOLORES NOLAZCO, GABY RAJFER, JACOB GONZALEZ‐CADAVID, NESTOR F. |
| description | OBJECTIVES
To determine whether corporal veno‐occlusive dysfunction (CVOD), corporal smooth muscle (SM) loss, fibrosis and oxidative stress occur in a rat model of type 2 diabetes, and whether these are counteracted by pioglitazone, as pioglitazone is vasculoprotective, and corporal SM is an extension of arterial SM.
MATERIALS AND METHODS
Male obese Zucker fa/fa rats were fed chow containing 0%, 0.001% or 0.02% pioglitazone for 2 or 5 months, using untreated lean Zucker and Fischer 344 rats as controls. Functional changes were determined by dynamic‐infusion cavernosometry. Histological changes were assessed by histochemistry and immunohistochemistry followed by quantitative image analysis and/or quantitative Western blot.
RESULTS
CVOD was detected at 4.5 months of diabetes, accompanied by a lower corporal SM/collagen ratio, and increases in collagen, collagen III/I ratio, apoptotic index, and systemic and tissue oxidative stress. In the short‐term treatment, high‐dose pioglitazone normalized glycaemia and ameliorated fibrosis and oxidative stress, but induced CVOD, whereas the effects with the low dose were not significant. However, low‐dose pioglitazone for 5 months corrected all alterations.
CONCLUSION
Type 2 diabetes in Zucker fa/fa rats was associated with penile corporal fibrosis, oxidative stress, and CVOD, which were ameliorated by long‐term low‐dose pioglitazone, suggesting that this drug might protect the SM, independently from its antidiabetic effect. |
| doi_str_mv | 10.1111/j.1464-410X.2006.06268.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68625754</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68625754</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4638-8e7ce4a0d089789a18b15dfc23ddf1d0bf340876a22a3e97c005df0a37cecccb3</originalsourceid><addsrcrecordid>eNqNkM1u3CAQgFHUKj_bvELFJb3ZAf9gfMghWTU_1UrtoZFyQxiGipVtXLDT3ZzyCHnGPklxdttcy4UZ5pth9CGEKUlpPOfrlBasSApKHtKMEJYSljGebg7Q8b_Cu78xqdkROglhTUh8YOUhOqKM55SW5TEy36z70dpRPrke8ODhEfoxYOX84LxscUzd7-cXp1Q7BfsIWG-DmXo1Wtdj22OJvRxx5zS02Bk8bgfAGdZWNjBCwB20cfgUPqD3RrYBTvf3At1ff_6-vE1WX2_ulperRBUs5wmHSkEhiSa8rngtKW9oqY3Kcq0N1aQxeUF4xWSWyRzqShESy0TmsU0p1eQL9Gk3d_Du5wRhFJ0NKi4he3BTEIyzrKzKIoJ8ByrvQvBgxOBtJ_1WUCJmx2ItZn1iVilmx-LVsdjE1o_7P6amA_3WuJcagbM9IIOSrfGyVza8cRWveMZ55C523C_bwva_FxBXX-7nKP8DjWCbMw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68625754</pqid></control><display><type>article</type><title>Pioglitazone prevents corporal veno‐occlusive dysfunction in a rat model of type 2 diabetes mellitus</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>KOVANECZ, ISTVAN ; FERRINI, MONICA G. ; VERNET, DOLORES ; NOLAZCO, GABY ; RAJFER, JACOB ; GONZALEZ‐CADAVID, NESTOR F.</creator><creatorcontrib>KOVANECZ, ISTVAN ; FERRINI, MONICA G. ; VERNET, DOLORES ; NOLAZCO, GABY ; RAJFER, JACOB ; GONZALEZ‐CADAVID, NESTOR F.</creatorcontrib><description>OBJECTIVES
To determine whether corporal veno‐occlusive dysfunction (CVOD), corporal smooth muscle (SM) loss, fibrosis and oxidative stress occur in a rat model of type 2 diabetes, and whether these are counteracted by pioglitazone, as pioglitazone is vasculoprotective, and corporal SM is an extension of arterial SM.
MATERIALS AND METHODS
Male obese Zucker fa/fa rats were fed chow containing 0%, 0.001% or 0.02% pioglitazone for 2 or 5 months, using untreated lean Zucker and Fischer 344 rats as controls. Functional changes were determined by dynamic‐infusion cavernosometry. Histological changes were assessed by histochemistry and immunohistochemistry followed by quantitative image analysis and/or quantitative Western blot.
RESULTS
CVOD was detected at 4.5 months of diabetes, accompanied by a lower corporal SM/collagen ratio, and increases in collagen, collagen III/I ratio, apoptotic index, and systemic and tissue oxidative stress. In the short‐term treatment, high‐dose pioglitazone normalized glycaemia and ameliorated fibrosis and oxidative stress, but induced CVOD, whereas the effects with the low dose were not significant. However, low‐dose pioglitazone for 5 months corrected all alterations.
CONCLUSION
Type 2 diabetes in Zucker fa/fa rats was associated with penile corporal fibrosis, oxidative stress, and CVOD, which were ameliorated by long‐term low‐dose pioglitazone, suggesting that this drug might protect the SM, independently from its antidiabetic effect.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/j.1464-410X.2006.06268.x</identifier><identifier>PMID: 16831155</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Apoptosis - drug effects ; Associated diseases and complications ; Biological and medical sciences ; Blotting, Western ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - pathology ; Diabetes. Impaired glucose tolerance ; Diabetic Angiopathies - drug therapy ; Diabetic Angiopathies - pathology ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; erectile dysfunction ; Fibrosis ; Hypoglycemic Agents - therapeutic use ; Impotence, Vasculogenic - drug therapy ; Impotence, Vasculogenic - pathology ; Male ; Medical sciences ; Nephrology. Urinary tract diseases ; Oxidative Stress ; Penis - pathology ; Rats ; Rats, Zucker ; smooth muscle ; thiazolidenediones ; Zucker fa/fa rat</subject><ispartof>BJU international, 2006-07, Vol.98 (1), p.116-124</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4638-8e7ce4a0d089789a18b15dfc23ddf1d0bf340876a22a3e97c005df0a37cecccb3</citedby><cites>FETCH-LOGICAL-c4638-8e7ce4a0d089789a18b15dfc23ddf1d0bf340876a22a3e97c005df0a37cecccb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1464-410X.2006.06268.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1464-410X.2006.06268.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17878288$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16831155$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KOVANECZ, ISTVAN</creatorcontrib><creatorcontrib>FERRINI, MONICA G.</creatorcontrib><creatorcontrib>VERNET, DOLORES</creatorcontrib><creatorcontrib>NOLAZCO, GABY</creatorcontrib><creatorcontrib>RAJFER, JACOB</creatorcontrib><creatorcontrib>GONZALEZ‐CADAVID, NESTOR F.</creatorcontrib><title>Pioglitazone prevents corporal veno‐occlusive dysfunction in a rat model of type 2 diabetes mellitus</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>OBJECTIVES
To determine whether corporal veno‐occlusive dysfunction (CVOD), corporal smooth muscle (SM) loss, fibrosis and oxidative stress occur in a rat model of type 2 diabetes, and whether these are counteracted by pioglitazone, as pioglitazone is vasculoprotective, and corporal SM is an extension of arterial SM.
MATERIALS AND METHODS
Male obese Zucker fa/fa rats were fed chow containing 0%, 0.001% or 0.02% pioglitazone for 2 or 5 months, using untreated lean Zucker and Fischer 344 rats as controls. Functional changes were determined by dynamic‐infusion cavernosometry. Histological changes were assessed by histochemistry and immunohistochemistry followed by quantitative image analysis and/or quantitative Western blot.
RESULTS
CVOD was detected at 4.5 months of diabetes, accompanied by a lower corporal SM/collagen ratio, and increases in collagen, collagen III/I ratio, apoptotic index, and systemic and tissue oxidative stress. In the short‐term treatment, high‐dose pioglitazone normalized glycaemia and ameliorated fibrosis and oxidative stress, but induced CVOD, whereas the effects with the low dose were not significant. However, low‐dose pioglitazone for 5 months corrected all alterations.
CONCLUSION
Type 2 diabetes in Zucker fa/fa rats was associated with penile corporal fibrosis, oxidative stress, and CVOD, which were ameliorated by long‐term low‐dose pioglitazone, suggesting that this drug might protect the SM, independently from its antidiabetic effect.</description><subject>Animals</subject><subject>Apoptosis - drug effects</subject><subject>Associated diseases and complications</subject><subject>Biological and medical sciences</subject><subject>Blotting, Western</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - pathology</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic Angiopathies - drug therapy</subject><subject>Diabetic Angiopathies - pathology</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>erectile dysfunction</subject><subject>Fibrosis</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Impotence, Vasculogenic - drug therapy</subject><subject>Impotence, Vasculogenic - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Oxidative Stress</subject><subject>Penis - pathology</subject><subject>Rats</subject><subject>Rats, Zucker</subject><subject>smooth muscle</subject><subject>thiazolidenediones</subject><subject>Zucker fa/fa rat</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM1u3CAQgFHUKj_bvELFJb3ZAf9gfMghWTU_1UrtoZFyQxiGipVtXLDT3ZzyCHnGPklxdttcy4UZ5pth9CGEKUlpPOfrlBasSApKHtKMEJYSljGebg7Q8b_Cu78xqdkROglhTUh8YOUhOqKM55SW5TEy36z70dpRPrke8ODhEfoxYOX84LxscUzd7-cXp1Q7BfsIWG-DmXo1Wtdj22OJvRxx5zS02Bk8bgfAGdZWNjBCwB20cfgUPqD3RrYBTvf3At1ff_6-vE1WX2_ulperRBUs5wmHSkEhiSa8rngtKW9oqY3Kcq0N1aQxeUF4xWSWyRzqShESy0TmsU0p1eQL9Gk3d_Du5wRhFJ0NKi4he3BTEIyzrKzKIoJ8ByrvQvBgxOBtJ_1WUCJmx2ItZn1iVilmx-LVsdjE1o_7P6amA_3WuJcagbM9IIOSrfGyVza8cRWveMZ55C523C_bwva_FxBXX-7nKP8DjWCbMw</recordid><startdate>200607</startdate><enddate>200607</enddate><creator>KOVANECZ, ISTVAN</creator><creator>FERRINI, MONICA G.</creator><creator>VERNET, DOLORES</creator><creator>NOLAZCO, GABY</creator><creator>RAJFER, JACOB</creator><creator>GONZALEZ‐CADAVID, NESTOR F.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200607</creationdate><title>Pioglitazone prevents corporal veno‐occlusive dysfunction in a rat model of type 2 diabetes mellitus</title><author>KOVANECZ, ISTVAN ; FERRINI, MONICA G. ; VERNET, DOLORES ; NOLAZCO, GABY ; RAJFER, JACOB ; GONZALEZ‐CADAVID, NESTOR F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4638-8e7ce4a0d089789a18b15dfc23ddf1d0bf340876a22a3e97c005df0a37cecccb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Apoptosis - drug effects</topic><topic>Associated diseases and complications</topic><topic>Biological and medical sciences</topic><topic>Blotting, Western</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - pathology</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic Angiopathies - drug therapy</topic><topic>Diabetic Angiopathies - pathology</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>erectile dysfunction</topic><topic>Fibrosis</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Impotence, Vasculogenic - drug therapy</topic><topic>Impotence, Vasculogenic - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Oxidative Stress</topic><topic>Penis - pathology</topic><topic>Rats</topic><topic>Rats, Zucker</topic><topic>smooth muscle</topic><topic>thiazolidenediones</topic><topic>Zucker fa/fa rat</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KOVANECZ, ISTVAN</creatorcontrib><creatorcontrib>FERRINI, MONICA G.</creatorcontrib><creatorcontrib>VERNET, DOLORES</creatorcontrib><creatorcontrib>NOLAZCO, GABY</creatorcontrib><creatorcontrib>RAJFER, JACOB</creatorcontrib><creatorcontrib>GONZALEZ‐CADAVID, NESTOR F.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KOVANECZ, ISTVAN</au><au>FERRINI, MONICA G.</au><au>VERNET, DOLORES</au><au>NOLAZCO, GABY</au><au>RAJFER, JACOB</au><au>GONZALEZ‐CADAVID, NESTOR F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pioglitazone prevents corporal veno‐occlusive dysfunction in a rat model of type 2 diabetes mellitus</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2006-07</date><risdate>2006</risdate><volume>98</volume><issue>1</issue><spage>116</spage><epage>124</epage><pages>116-124</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><abstract>OBJECTIVES
To determine whether corporal veno‐occlusive dysfunction (CVOD), corporal smooth muscle (SM) loss, fibrosis and oxidative stress occur in a rat model of type 2 diabetes, and whether these are counteracted by pioglitazone, as pioglitazone is vasculoprotective, and corporal SM is an extension of arterial SM.
MATERIALS AND METHODS
Male obese Zucker fa/fa rats were fed chow containing 0%, 0.001% or 0.02% pioglitazone for 2 or 5 months, using untreated lean Zucker and Fischer 344 rats as controls. Functional changes were determined by dynamic‐infusion cavernosometry. Histological changes were assessed by histochemistry and immunohistochemistry followed by quantitative image analysis and/or quantitative Western blot.
RESULTS
CVOD was detected at 4.5 months of diabetes, accompanied by a lower corporal SM/collagen ratio, and increases in collagen, collagen III/I ratio, apoptotic index, and systemic and tissue oxidative stress. In the short‐term treatment, high‐dose pioglitazone normalized glycaemia and ameliorated fibrosis and oxidative stress, but induced CVOD, whereas the effects with the low dose were not significant. However, low‐dose pioglitazone for 5 months corrected all alterations.
CONCLUSION
Type 2 diabetes in Zucker fa/fa rats was associated with penile corporal fibrosis, oxidative stress, and CVOD, which were ameliorated by long‐term low‐dose pioglitazone, suggesting that this drug might protect the SM, independently from its antidiabetic effect.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>16831155</pmid><doi>10.1111/j.1464-410X.2006.06268.x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2006-07, Vol.98 (1), p.116-124 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68625754 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animals Apoptosis - drug effects Associated diseases and complications Biological and medical sciences Blotting, Western Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - pathology Diabetes. Impaired glucose tolerance Diabetic Angiopathies - drug therapy Diabetic Angiopathies - pathology Endocrine pancreas. Apud cells (diseases) Endocrinopathies erectile dysfunction Fibrosis Hypoglycemic Agents - therapeutic use Impotence, Vasculogenic - drug therapy Impotence, Vasculogenic - pathology Male Medical sciences Nephrology. Urinary tract diseases Oxidative Stress Penis - pathology Rats Rats, Zucker smooth muscle thiazolidenediones Zucker fa/fa rat |
| title | Pioglitazone prevents corporal veno‐occlusive dysfunction in a rat model of type 2 diabetes mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T21%3A02%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pioglitazone%20prevents%20corporal%20veno%E2%80%90occlusive%20dysfunction%20in%20a%20rat%20model%20of%20type%202%20diabetes%20mellitus&rft.jtitle=BJU%20international&rft.au=KOVANECZ,%20ISTVAN&rft.date=2006-07&rft.volume=98&rft.issue=1&rft.spage=116&rft.epage=124&rft.pages=116-124&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1111/j.1464-410X.2006.06268.x&rft_dat=%3Cproquest_cross%3E68625754%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68625754&rft_id=info:pmid/16831155&rfr_iscdi=true |